Sugi Predict

Sugi Predict / Compounds / SCHEMBL7604948

SCHEMBL7604948

SCHEMBL7604948

O=[N+]([O-])c1cccc2c1CCCN2

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 3/20 0.47
▸ PNMT P11086 1/20 0.41
▸ TDP1 Q9NUW8 3/20 0.41
▸ TSHR P16473 3/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ GPR35 Q9HC97 2/20 0.40
▸ ALDH1A1 P00352 2/20 0.40
▸ GRIA1 P42261 1/20 0.40
▸ GRIA2 P42262 1/20 0.40
▸ GRIA3 P42263 1/20 0.40
▸ GRIA4 P48058 1/20 0.40
▸ HSD17B10 Q99714 1/20 0.39
▸ LMNA P02545 1/20 0.38
▸ MEN1 O00255 2/20 0.37
▸ KMT2A Q03164 2/20 0.37
▸ L3MBTL1 Q9Y468 2/20 0.37
▸ KDM4E B2RXH2 1/20 0.37
▸ GAA P10253 1/20 0.37
▸ HTT P42858 1/20 0.37
▸ PDE10A Q9Y233 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL256723 0.90 MAPT (0.45) MAPTPNMTTDP1TSHRSMN1; SMN2
Acetic Acid SCHEMBL28293668 0.81 TDP1 (0.42) MAPTPNMTTDP1TSHRSMN1; SMN2
SCHEMBL28330461 0.79 ALDH1A1 (0.42) MAPTTDP1TSHRSMN1; SMN2GPR35
SCHEMBL2061513 0.79 PNMT (0.50) MAPTPNMTTDP1TSHRSMN1; SMN2
SCHEMBL6783794 0.78 GRIA1 (0.41) MAPTTDP1TSHRSMN1; SMN2ALDH1A1
Quinoline SCHEMBL28062786 0.75 POLB (0.49) MAPTTDP1ALDH1A1LMNAMEN1
SCHEMBL9501421 0.74 TDP1 (0.45) MAPTPNMTTDP1TSHRSMN1; SMN2
SCHEMBL31357065 0.74 TDP1 (0.45) MAPTPNMTTDP1TSHRSMN1; SMN2
SCHEMBL8805931 0.73 PNMT (0.44) MAPTPNMTTDP1TSHRSMN1; SMN2
SCHEMBL10400093 0.73 SRC (0.47) MAPTPNMTTDP1TSHRSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110511182-B Method for synthesizing 7-nitro-1,2,3,4-tetrahydroquinoline by continuous flow reaction 上海昕凯医药科技有限公司 2023-01-17 — — CN claimed
EP-3630770-B1 PYRAZOLO[3,4-B]PYRAZINE DERIVATIVES AS SHP2 PHOSPHATASE INHIBITORS RELAY THERAPEUTICS INC (US) 2024-08-28 — — EP disclosed
US-20240262792-A1 USP30 INHIBITORS AND USES THEREOF VINCERE BIOSCIENCES, INC. 2024-08-08 — — US disclosed
US-11845724-B2 USP30 inhibitors and uses thereof VINCERE BIOSCIENCES, INC. (US) 2023-12-19 — — US disclosed
US-11591336-B2 Substituted pyrazolo[3,4-b]pyrazines as SHP2 phosphatase inhibitors D. E. SHAW RESEARCH, LLC (US) 2023-02-28 — — US disclosed
CN-110511182-B Method for synthesizing 7-nitro-1,2,3,4-tetrahydroquinoline by continuous flow reaction 上海昕凯医药科技有限公司 2023-01-17 — — CN disclosed
CN-110511182-B Method for synthesizing 7-nitro-1,2,3,4-tetrahydroquinoline by continuous flow reaction 上海昕凯医药科技有限公司 2023-01-17 — — CN disclosed
US-20220315531-A1 USP30 INHIBITORS AND USES THEREOF VINCERE BIOSCIENCES, INC. 2022-10-06 — — US disclosed
CN-115038688-A USP30 inhibitors and uses thereof 文森雷生物科学股份有限公司 2022-09-09 — — CN disclosed
EP-4028385-A1 USP30 INHIBITORS AND USES THEREOF Vincere Biosciences, Inc. (US) 2022-07-20 — — EP disclosed
US-8877707-B2 Inhibitors of HCV NS5A PRESIDIO PHARMACEUTICALS, INC. (US) 2014-11-04 — — US disclosed
EP-2682393-A1 Inhibitors of HCV NS5A comprising a bicyclic core. Presidio Pharmaceuticals, Inc. (US) 2014-01-08 — — EP disclosed
US-20130203656-A1 INHIBITORS OF HCV NS5A PRESIDIO PHARMACEUTICALS, INC. (US) 2013-08-08 — — US disclosed
US-20130203656-A1 INHIBITORS OF HCV NS5A PRESIDIO PHARMACEUTICALS, INC. (US) 2013-08-08 — — US disclosed
US-20130096101-A1 INHIBITORS OF HCV NS5A PRESIDIO PHARMACEUTICALS, INC. (US) 2013-04-18 — — US disclosed
WO-2010065674-A9 INHIBITORS OF HCV NS5A PRESIDIO PHARMACEUTICALS, INC. (US) 2012-05-31 — — WO disclosed
US-20120122864-A1 INHIBITORS OF HCV NS5A PRESIDIO PHARMACEUTICALS, INC. (US) 2012-05-17 — — US disclosed
US-20120122864-A1 INHIBITORS OF HCV NS5A PRESIDIO PHARMACEUTICALS, INC. (US) 2012-05-17 — — US disclosed
WO-2011149856-A1 INHIBITORS OF HCV NS5A PRESIDIO PHARMACEUTICALS, INC. (US) 2011-12-01 — — WO disclosed
WO-2010065674-A1 INHIBITORS OF HCV NS5A PRESIDIO PHARMACEUTICALS, INC. (US) 2010-06-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130096101-A1 INHIBITORS OF HCV NS5A HAVCR2, MAVS, EIF2AK2 MAPT 3230/4885PNMT 4102/4885TDP1 4284/4885
US-20120122864-A1 INHIBITORS OF HCV NS5A HAVCR2, MAVS, EIF2AK2 MAPT 3250/4885PNMT 3973/4885TDP1 4237/4885
US-11591336-B2 Substituted pyrazolo[3,4-b]pyrazines as SHP2 phosphatase inhibitors PTPN5, PTPN2, PTPN1 MAPT 4183/4885PNMT 4694/4885TDP1 1939/4885
US-20130203656-A1 INHIBITORS OF HCV NS5A HAVCR2, MAVS, EIF2AK2 MAPT 3250/4885PNMT 3973/4885TDP1 4237/4885
US-11845724-B2 USP30 inhibitors and uses thereof USP30, USP28, USP1 MAPT 2434/4885PNMT 3502/4885TDP1 1080/4885
US-20220315531-A1 USP30 INHIBITORS AND USES THEREOF USP30, USP28, USP1 MAPT 2434/4885PNMT 3502/4885TDP1 1080/4885
US-20240262792-A1 USP30 INHIBITORS AND USES THEREOF USP30, USP28, USP1 MAPT 2434/4885PNMT 3502/4885TDP1 1080/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.